Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Response
Publication
, Journal Article
Granger, CB; Mahaffey, KW; Weaver, WD; Theroux, P; Hochman, JS; Filloon, TG; Todaro, TG; Rollins, S; Mojcik, CF; Nicolau, JC; Ruzyllo, W ...
Published in: CIRCULATION
April 27, 2004
Duke Scholars
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
April 27, 2004
Volume
109
Issue
16
Start / End Page
E195 / E196
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Granger, C. B., Mahaffey, K. W., Weaver, W. D., Theroux, P., Hochman, J. S., Filloon, T. G., … Armstrong, P. W. (2004). Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Response. CIRCULATION, 109(16), E195–E196.
Granger, C. B., K. W. Mahaffey, W. D. Weaver, P. Theroux, J. S. Hochman, T. G. Filloon, T. G. Todaro, et al. “Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Response.” CIRCULATION 109, no. 16 (April 27, 2004): E195–96.
Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, et al. Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Response. CIRCULATION. 2004 Apr 27;109(16):E195–6.
Granger, C. B., et al. “Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Response.” CIRCULATION, vol. 109, no. 16, LIPPINCOTT WILLIAMS & WILKINS, Apr. 2004, pp. E195–96.
Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Todaro TG, Rollins S, Mojcik CF, Nicolau JC, Ruzyllo W, Armstrong PW. Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Response. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2004 Apr 27;109(16):E195–E196.
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
April 27, 2004
Volume
109
Issue
16
Start / End Page
E195 / E196
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology